SARS-CoV-2 vaccines for cancer patients: a call to action.

Autor: Corti C; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy., Crimini E; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy., Tarantino P; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy., Pravettoni G; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, IRCCS, Milan, Italy., Eggermont AMM; Research Directorate, Princess Máxima Center, Utrecht, the Netherlands., Delaloge S; Institut Gustave Roussy, Villejuif, France., Curigliano G; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 May; Vol. 148, pp. 316-327. Date of Electronic Publication: 2021 Feb 25.
DOI: 10.1016/j.ejca.2021.01.046
Abstrakt: Coronavirus disease 2019 (COVID-19) has affected more than 96 million people worldwide, leading the World Health Organization (WHO) to declare a pandemic in March 2020. Although an optimal medical treatment of COVID-19 remains uncertain, an unprecedented global effort to develop an effective vaccine hopes to restore pre-pandemic conditions. Since cancer patients as a group have been shown to be at a higher risk of severe COVID-19, the development of safe and effective vaccines is crucial. However, cancer patients may be underrepresented in ongoing phase 3 randomised clinical trials investigating COVID-19 vaccines. Therefore, we encourage stakeholders to provide real-time data about the characteristics of recruited participants, including clearly identifiable subgroups, like cancer patients, with sample sizes large enough to determine safety and efficacy. Moreover, we envisage a prompt implementation of suitable registries for pharmacovigilance reporting, in order to monitor the effects of COVID-19 vaccines and immunisation rates in patients with cancer. That said, data extrapolation from other vaccine trials (e.g. anti-influenza virus) showed a favourable safety and efficacy profile for cancer patients. On the basis of the evidence discussed, we believe that the benefits of the vaccination outweigh the risks. Consequently, healthcare authorities should prioritise vaccinations for cancer patients, with the time-point of administration agreed on a case-by-case basis. In this regard, the American Society of Clinical Oncology and the European Society of Medical Oncology are advocating for cancer patients a high priority status, in the hope of attenuating the consequences of the pandemic in this particularly vulnerable population.
Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CC, EC, PT and GP have no potential conflicts of interest to disclose. AMME served as consultant or advisor for Ellipses Pharma, GlaxoSmithKline, ISA Pharmaceuticals, MSD, Novartis, Pfizer, Sellas Life Sciences, Skyline Diagnostics, BioInvent, IO Biotech, CatalYm and Nektar, served on the speaker's bureau for MSD, BIOCAD, received travel funding from Bristol Myers Squibb and received honoraria from Ellipses Pharma, GlaxoSmithKline, ISA Pharmaceuticals, MSD, Novartis, Pfizer, Sellas Life Sciences, Skyline Diagnostics, BIOCAD, CatalYm, BioInvent, IO Biotech, Nektar, provided expert testimony for Novartis and has stock and other ownership interest with RiverD, Skyline Diagnostics, Theranovir, all outside the submitted work. SD served as consultant or advisor for AstraZeneca, received research funding from AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Puma (Inst), Eli Lilly (Inst), Novartis (Inst), Sanofi (Inst) and received travel funding from Pfizer, AstraZeneca and Roche. GC served as consultant or advisor for Roche, Lilly and Bristol-Myers Squibb, served on the speaker's bureau for Roche, Pfizer and Lilly, received travel funding from Pfizer and Roche and received honoraria from Roche, Pfizer, Lilly, Novartis and SEAGEN, all outside the submitted work.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: